Abeona Therapeutics Inc vs Smith & Nephew plc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Smith & Nephew plc trades at $30.05 (market cap $12.54B). The key difference: Smith & Nephew plc is far larger — about 29.8× Abeona Therapeutics Inc's market cap, and Smith & Nephew plc pays a 2.65% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | SNN | |
|---|---|---|
Market Cap | $421.19M | $12.54B |
Sector | Health | Health |
52-Week High | $7.45 | $38.70 |
52-Week Low | $4.17 | $28.73 |
Enterprise Value | $276.10M | $15.57B |
Dividend Yield | — | 2.65% |
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →